文献速递头颈外科

头颈癌患者与其他癌症患者共病抑郁的比较

Comorbid Depression in Patients With Head and Neck Cancer Compared With Other Cancers.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2024-01-01

这项回顾性队列研究利用2019年美国国家健康访谈调查数据,比较了头颈癌(HNC)患者与其他癌症患者的抑郁患病率。HNC患者PHQ-8筛查任何抑郁的患病率为40.1%,其他癌症患者为22.3%;多变量逻辑回归显示HNC与抑郁可能性增加相关(OR 2.94,95%CI 1.39-6.22)。尽管自报抑郁率和抗抑郁药使用率相似,HNC患者筛查阳性率更高,提示自报可能低估抑郁。

要点

  • HNC患者PHQ-8筛查任何抑郁的患病率为40.1%,其他癌症患者为22.3%。
  • 多变量分析中HNC与抑郁可能性增加相关(OR 2.94,95%CI 1.39-6.22)。
  • HNC患者与其他癌症患者自报抑郁率和抗抑郁药使用率相似,但筛查阳性率更高。

核心结论

  • 头颈癌患者在经验证的问卷上筛查抑郁阳性的可能性是其他癌症患者的两倍,尽管自报抑郁率和抗抑郁药使用率相似。
  • 作者认为自报抑郁可能导致该人群抑郁的低报和低治疗,因此需要进一步开展工作开发干预措施以改善头颈癌共病抑郁患者的识别和优化治疗。

研究设计与样本

  • 这项回顾性队列研究使用2019年美国国家健康访谈调查中18岁及以上癌症患者的人群水平数据,并完成个人健康问卷-8(PHQ-8)。
  • 分析于2023年8月7日至2024年4月5日进行。
  • 加权队列包含23 496 725名成人癌症患者,其中377 080例诊断为头颈癌(87.5%年龄51-84岁;77.9%男性)。

主要发现

  • PHQ-8任何抑郁(轻度、中度或重度)的患病率在头颈癌患者中为40.1%,在其他癌症患者中为22.3%。
  • 与其他癌症患者相比,头颈癌患者焦虑筛查阳性率相似(23.6% vs 16.0%;差值7.6%;95%CI -5.9%至21.1%),服用抗抑郁药率相似(10.1% vs 13.9%;差值-3.8%;95%CI -11.9%至4.4%),自报从不感到抑郁率相似(59.7% vs 53.7%;差值6.0%;95%CI -9.1%至21.0%)。
  • 多变量逻辑回归分析中,头颈癌与抑郁可能性增加相关(OR 2.94;95%CI 1.39-6.22)。
  • 其他与抑郁相关的因素包括未婚或未与伴侣同住(OR 1.94;95%CI 1.55-2.43)和焦虑(OR 23.14;95%CI 17.62-30.37)。

临床怎么用

  • 原文结论未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Depression is more prevalent among individuals with cancer than in the general population and is correlated with increased mortality in patients with head and neck cancer (HNC) in particular. OBJECTIVE: To compare the prevalence of depression between patients with HNC and patients with other cancers. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used population-level data on patients aged 18 years or older with cancer who participated in the 2019 National Health Interview Survey and had completed the Personal Health Questionnaire-8 (PHQ-8). The analysis was performed between August 7, 2023, and April 5, 2024. EXPOSURE: Any cancer diagnosis. MAIN OUTCOMES AND MEASURES: The main outcome was prevalence and severity of depression based on the PHQ-8. The magnitude of the difference in baseline characteristics was measured between patients with HNC and those with other cancer types, and 95% CIs were used to measure the precision of these estimates. Multivariable logistic regressions were used to evaluate the association of demographic, socioeconomic, anxiety, and clinical variables with depression. RESULTS: From a weighted cohort of 23 496 725 adult patients with cancer, 377 080 were diagnosed with HNC (87.5% aged 51-84 years; 77.9% male). The prevalence of any depression on the PHQ-8 (mild, moderate, or severe) was 40.1% in patients with HNC vs 22.3% in patients with other cancers. Compared with patients with other cancers, patients with HNC were equally likely to screen positive for anxiety (23.6% vs 16.0%; difference, 7.6%; 95% CI, -5.9% to 21.1%), take medication for depression (10.1% vs 13.9%; difference, -3.8%; 95% CI, -11.9% to 4.4%), and state that they never feel depressed (59.7% vs 53.7%; difference, 6.0%; 95% CI, -9.1% to 21.0%). On multivariable logistic regression analysis, having HNC was associated with an increased likelihood of depression (odds ratio [OR], 2.94; 95% CI, 1.39-6.22). Other factors associated with depression were being unmarried or not living with a partner (OR, 1.94; 95% CI, 1.55-2.43) and having anxiety (OR, 23.14; 95% CI, 17.62-30.37). CONCLUSIONS AND RELEVANCE: This cohort study found that patients with HNC were twice as likely to screen positive for depression on a validated survey than those with other cancers, despite having similar rates of self-reported depression and depression medication use. These findings suggest that self-reporting of depression may result in underreporting and undertreatment in this population and, thus, a need for further work in developing interventions to improve identification of and optimize treatment for patients with HNC and comorbid depression.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Martinez MC, Finegersh A, Baik FM, et al. Comorbid Depression in Patients With Head and Neck Cancer Compared With Other Cancers. JAMA Otolaryngol Head Neck Surg. 2024. PMID: 39446380. doi:10.1001/jamaoto.2024.3233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。